U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 901 - 910 of 13408 results

Status:
Investigational
Source:
INN:dimepregnen
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Dimepregnen is an antiestrogen agent.
Status:
Investigational
Source:
NCT00430300: Phase 2 Interventional Terminated Pulmonary Disease, Chronic Obstructive
(2007)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)



UK-432097 is a selective adenosine A2a agonist which was in development with Pfizer as an inhaled treatment for asthma and chronic obstructive pulmonary disease. UK-432097 had been in phase II clinical trials by Pfizer for the treatment of chronic obstructive pulmonary disease (COPD). However, this study was terminated prematurely due to futility based on results of interim analysis.
Status:
Investigational
Source:
INN:primidolol
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Primidolol (also known as UK-11,443) is an imidazolidinone derivative patented by American pharmaceutical corporation Pfizer Corp as a specific β-adrenergic blocker. In clinical trials, Primidolol shows some antihypertensive activity but the overall change in the cardiovascular parameters failed to demonstrate a significant difference compared to placebo.
Status:
Investigational
Source:
INN:imitrodast
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Imitrodast is thianaphthene derivative and thromboxane A2 inhibitor patented by Japanese pharmaceutical company Sankyo Co as antithrombotic agent.
Status:
Investigational
Source:
INN:norgesterone
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Norgesterone (norvinodrel, vinylestrenolone) is a progestin medication which was formerly used in birth control pills for women. The compound shows no androgenic and very little estrogenic activity; its progestational effect, as well as other properties, suggests its use as claudogenic agent. Norgesterone is an agonist of the progesterone receptor. It was used in combination with ethinylestradiol in birth control pills to prevent pregnancy.
Status:
Investigational
Source:
INN:trodusquemine [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Trodusquemine (MSI-1436) is a "first-in-class" highly selective non-competitive, allosteric inhibitor of PTP1B that can cross the blood-brain barrier to suppress feeding and promote insulin sensitivity and glycemic control. Trodusquemine is a naturally occurring cholestane that can be purified from the liver of the dogfish shark, Squalus acanthias, but it can also be manufactured synthetically by a fairly laborious process that requires several weeks. Trodusquemine has potential hypoglycemic, anti-diabetic, anti-obesity, and antineoplastic activities. Upon administration, trodusquemine selectively targets and inhibits PTP1B, thereby preventing PTP1B-mediated signaling. This prevents the dephosphorylation of the insulin receptor, which improves insulin signaling and insulin sensitivity, and decreases blood glucose levels. In susceptible cancer cells, inhibition of PTP1B causes a reduction of tumor cell proliferation.
Status:
Investigational
Source:
INN:sonedenoson [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Sonedenoson (MRE0094) is a topical adenosine A2A-receptor agonist which was under clinical development for the treatment of for diabetic foot ulcer. The compound was originally developed by New York University, and licensed to Medco Research (King Pharmaceuticals). King Pharmaceuticals was acquired by Pfizer in 2010. Sonedenoson has been in phase II clinical trials for the treatment of chronic diabetic neuropathic foot ulcers. However, this research has been discontinued.
Status:
Investigational
Source:
INN:cimaterol
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)


Conditions:

Cimaterol is a chemically stable nonselective agonist β1-, β2-, and β3-adrenoceptors. Cimaterol is used in sport as a stimulant and a fat burner that assists bodybuilders and strength athletes to get rid of body fats. Aside from shedding off fats, another benefit for using cimaterol for athletes is a boost in strength as well as an increase in muscle size or lean body mass. The increase in muscle size has been seen in previous animal studies when cimaterol is used. However, the reason behind the muscle gain is not identified yet, but the body has a very different response compared from taking in anabolic steroids. Experts in the field are saying that the increased nitrogen retention, that is known to cause by cimaterol, maybe the reason behind the muscle gain. Another great thing about Cimaterol is that, it can improve blood flow.
Status:
Investigational
Source:
INN:dacuronium bromide
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Dacuronium is an aminosteroid, acting as a competitive antagonist of nicotinic acetylcholine receptors. In animals, dacuronium worked as a short-acting muscle relaxant with a rapid onset of action. In a clinical trial, dacuronium was markedly less potent than tubocurarine and did not show a rapid recovery from its action.
Status:
Investigational
Source:
INN:roxibolone
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Roxibolone, an androstane derivative, possesses the anti-glucocorticoid activity and devoid of any affinity for the androgenic prostate and muscle receptors. This anabolic drug has never been marketed.